Laboratorios Rovi : Q4 2022 conference call highlights
>Conference call highlights - i/ Okedi ramp-up in Europe going according to plan. Treatment already launched in Germany, Spain, and UK. Portugal, France, Italy, Austria, Poland, and the Nordics to follow in 2023. Company expects a gradual increase in sales and stressed that it treats chronic disease like schizophrenia and as a result penetration is going to be slow. Management is ‘very excited’ about the feedback they are collecting from the medical community especial...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.